Vaxcyte, Inc. (PCVX) Stock
PCVX Key Statistics
About Vaxcyte, Inc.
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
CEO: Grant E. Pickering. Company website
PCVX — Frequently Asked Questions
What is the PCVX stock price today?
Vaxcyte, Inc. (PCVX) trades at $68.62, up 3.41% on the day, as of Nov 12, 2026 09:38 UTC.
What is Vaxcyte, Inc.'s market cap?
Vaxcyte, Inc. has a market capitalisation of $10.80B, calculated from the live PCVX share price and shares outstanding.
What is the P/E ratio of PCVX?
PCVX has no meaningful price-to-earnings ratio: Vaxcyte, Inc. lost $8.07 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Vaxcyte, Inc. make?
Vaxcyte, Inc. generated revenue of $0.00 over the trailing twelve months.
What is the 52-week range for PCVX?
PCVX has traded between $40.14 and $90.75 over the past 52 weeks, and the last price is 24.4% below that high.
Is Vaxcyte, Inc. profitable?
Yes. Vaxcyte, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
What is the analyst price target for PCVX?
Wall Street analysts rate PCVX Buy, with an average price target of $122.33, 78.3% above the current price.
What sector is Vaxcyte, Inc. in?
Vaxcyte, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Vaxcyte, Inc.?
Grant E. Pickering is the chief executive of Vaxcyte, Inc., which employs 507 people.
Where can I track PCVX in real time?
QFI Terminal shows PCVX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See PCVX live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open PCVX in Terminal See plans